Get started

Buy-signal

AEZS European approval to market MacrillenAEterna has a variety of new products in its pipeline. Macrilen, for example, is the first and only FDA-approved oral test for the diagnosis of Adult Growth Hormone Deficiency. AEterna received European approval to market Macrillen. Dr. Christian Strasburger: "Clinical studies have demonstrated that macimorelin is safer and much simpler to administer than the current methods of testing for insulin-induced hypoglycemia, and is well-tolerated by patients and reliable in diagnosing the condition.” I think AEZS is a sleeping giant. My price target is $1.25.
ALong
by TopgOptions
KMPH $50 Million Share Repurchase ProgramWhen most of the companies are diluting their shares and insiders are selling, KemPharm, Inc. (KMPH) does the opposite. Insiders are buying and the Board of Directors authorizes a program to repurchase up to $50 million of the Company’s outstanding stock valid through December 31, 2023. It is equivalent to 18% of KemPharm’s current market capitalization. Because of the short term puts i have 2 approaches for KMPH: dump to 7.17 and then go to 11.45 or bounce from the strong support which it has right now and go to $14.50 Looking forward to read your opinion about it.
KLong
by TopgOptions
Novonix ST: the upside prevails as long as 9.20 is support.Alternative scenario: the downside breakout of 9.20 would call for 7.10. My pivot point stands at 8.20. My preference: the upside prevails as long as 0.20 is support. Comment: the RSI is above its neutrality area at 50. The MACD is positive and above its signal line. The configuration is positive. Moreover, the stock is trading above both its 20 and 50 day moving average (respectively at 9.11 and 9.11). Trade Safe - Jimster45
ASX:NVXLong
by Jimster45
QNRX first FDA-approved treatment for Netherton SyndromeQuoin Pharmaceuticals (NASDAQ: QNRX ) is positioned to deliver the first FDA-approved treatment for Netherton Syndrome, a devastating disorder which affects 1 in every 200,000 people worldwide. This month, QNRX Signed Multiple Exclusive Distribution Agreements for in various regions of the globe for its Lead Asset, QRX003, for Netherton Syndrome. JMP Securities Initiated Coverage on Quoin Pharmaceuticals, Ltd. ( QNRX ) with a Market Outperform rating and a price target of 8usd. QNRX is massively oversold having a bullish divergence chart formation and fundamentals that can skyrocket the price to 12 usd in my opinion! Could be a Great buy opportunity at $1.91 today!
NASDAQ:QNRXLong
by TopgOptions
6
CWBR antiaging stock Price Target I think antiaging stocks will be the new FAANGS in 5 to 10 years. Immortality here, on earth, is the next frontier for the medicine. CohBar is developing mitochondria-based therapeutics for the treatment of chronic and age-related diseases. On 11/12/2021 Cantor Fitzgerald brokerage Initiated Coverage on CWBR with an Overweight rating and a price target of $2.50. This all time low looks like a great buy opportunity for me. Looking forward to read your opinion on it.
CLong
by TopgOptions
2
BKKT 15K calls expiring today + Dark Pool Prints More than 15K calls on BKKT are expiring today. and those are the calls from the last month only. The strike price varies from 14 to 75usd. The price of the stock is now 9.08usd. Yesterday we saw a volume of 32mil. Besides the 32mil, Dark Pool Prints were 33Mil. Dark pools are private exchanges not accessible by the investing public. Dark pools facilitate block trading by institutional investors who did not wish to impact the markets with their large orders and obtain adverse prices for their trades. I expect strong intraday volatility. i know it seems a little bit exaggerated, but i wouldn`t be surprised the see BKKT trading at 14-15usd. don`t forget that on Nov 21 BKKT was trading at $50.80. Looking forward to see how this trading day will end! What is your opinion about this trade?
NYSE:BKKTLong
by TopgOptions
1
QNRX Market Outperform Price Target !!Yesterday, JMP Securities Initiated Coverage on Quoin Pharmaceuticals, Ltd. (QNRX) with a Market Outperform rating and a price target of 8usd. Quoin Pharmaceuticals (NASDAQ: QNRX) is positioned to deliver the first FDA-approved treatment for Netherton Syndrome, a devastating disorder which affects 1 in every 200,000 people worldwide. This month, QNRX Signed Multiple Exclusive Distribution Agreements for in various regions of the globe for its Lead Asset, QRX003, for Netherton Syndrome. My price target is the 12usd resistance.
NASDAQ:QNRXLong
by TopgOptions
4
FWBI Opportunities in Multi-Billion-Dollar Commercial MarketsJames Sapirstein Chairman, President and CEO of First Wave BioPharma, Inc.: "We now have development- and clinical-stage programs that span six GI indications with significant market size opportunities, including: COVID-19-related GI infections (estimated at $10 billion, for COVID-19 related anti-virals); ulcerative colitis, ulcerative proctitis and ulcerative proctosigmoiditis (estimated at $5 billion); Crohn’s disease (estimated at $7.4 billion); immune checkpoint inhibitor-associated colitis (estimated at $22 billion for immune checkpoint inhibitors); and exocrine pancreatic insufficiency (EPI), a dangerous digestive disorder that afflicts most patients with cystic fibrosis and chronic pancreatitis (estimated at $1.6 billion)." Short term price target: 3.31, medium term: 6.44, end of 2022: 9.5.
FLong
by TopgOptions
730% upside stock according to CitigroupArdelyx , Inc. ARDX had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the company's FDA approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, in the second quarter of 2022, that has a potential peak in revenue greater than 500mil per year. Since ARDX’s Market Cap is only 191.663Mil, it has still a big upside potential. A decent 9X revenue means a potential 4.5 Billion market cap. That`s why in the last 2 days we saw volumes higher than 100Mil. Recently, on 11/30/2021, Yigal Nochomovitz from Citigroup Boosted the Price Target from Positive to Buy increasing the price target from $7.00 to $13.00. The price of the stock is now 1.7usd. My valuation is much higher! I look forward to read your opinion about it.
NASDAQ:ARDXLong
by TopgOptions
7